Novo Nordisk stock rises following regulatory clearance of Catalent deal

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) climbed 2% today after the company announced the fulfillment of all regulatory closing...
1 day ago
from: Investing.com

Catalent, Novo Holdings A/S, Novo Nordisk

More about this

- Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
Catalent says it worked on more than half of the new drugs approved by the FDA over the past 10 years.
from: Yahoo

- Novo Nordisk Secures Clearance for Strategic Acquisition
The latest update is out from Novo Nordisk ( ($NVO) ). Novo Nordisk has received clearance to proceed with its acquisition of three...
from: TipRanks

- Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they've received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal...
from: BioSpace

- We're reading about Novo Holdings-Catalent deal, Sanofi sanctions| STAT
A new study found that Novo Nordisk's blockbuster Ozempic treatment was linked to an increased risk of a rare form of vision loss.
from: STAT

- Novo Holdings Completes Regulatory Hurdles For Catalent Acquisition
After receiving a green light from both U.S. and EU antitrust regulators, all regulatory closing conditions relating to the review of Novo...
from: Contract Pharma

- Novo Nordisk chief "relieved" after approval of Catalent takeover
The approval from international authorities of Novo Holdings' acquisition of Catalent was expected, says Lars Fruergaard Jørgensen.
from: MedWatch

- Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The Federal Trade Commission declined to challenge the deal before a deadline passed, allowing the companies to move ahead with the $16.5...
from: BioPharma Dive

- Novo Nordisk’s New Deal May End Wegovy Shortages. It Could Reshape Pharma Industry Along the Way.
Novo Nordisk says that it has regulatory clearance to buy three key Catalent manufacturing sites used to make drugs like Wegovy,...
from: Barron's

- Danish pharma giant cleared to buy Catalent
Novo Nordisk announced in February that it's boosting manufacturing capacity for Wegovy, a popular weight loss drug and diabetes treatment.
from: Indiana Public Media